Profile data is unavailable for this security.
About the company
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
- Revenue in EUR (TTM)227.29m
- Net income in EUR86.13m
- Incorporated1986
- Employees477.00
- LocationPharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
- Phone+34 918466000
- Fax+34 918466001
- Websitehttps://www.pharmamar.com/es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fagron NV | 625.79m | 69.41m | 925.55m | 3.06k | 13.34 | 2.49 | 9.24 | 1.48 | 0.9508 | 0.9508 | 8.57 | 5.10 | 0.7136 | 3.50 | 10.55 | 204,438.40 | 7.95 | 7.30 | 9.93 | 9.98 | 42.18 | 44.05 | 11.14 | 10.41 | 1.23 | 14.06 | 0.5278 | 12.97 | 3.21 | 6.35 | 2.35 | -- | 7.01 | -- |
| Valneva SE | 393.81m | -158.52m | 926.84m | 700.00 | -- | 8.43 | 43.81 | 2.35 | -1.45 | -1.45 | 3.72 | 0.7952 | 0.5357 | 2.94 | 22.99 | 545,440.40 | -21.56 | -8.98 | -54.93 | -12.92 | 17.57 | 53.98 | -40.25 | -18.41 | 0.9368 | -4.48 | 0.5888 | -- | 215.52 | 29.91 | -14.03 | -- | 90.83 | -- |
| Puretech Health PLC | 17.75m | -12.90m | 930.78m | 95.00 | -- | 1.73 | -- | 52.44 | -0.0386 | -0.0386 | 0.0533 | 1.67 | 0.0216 | -- | 4.76 | 161,160.70 | -1.00 | 4.86 | -1.26 | 6.24 | -- | -- | -46.43 | 260.53 | -- | -- | 0.0771 | 0.00 | 47.76 | 31.45 | -1,111.83 | -- | 9.02 | -- |
| Vetoquinol SA | 536.71m | 48.07m | 1.00bn | 2.55k | 20.80 | 2.15 | 12.26 | 1.87 | 4.06 | 4.06 | 45.36 | 39.24 | 0.875 | 2.34 | 5.43 | 210,803.20 | 7.82 | 6.97 | 10.28 | 9.18 | 49.25 | 61.10 | 8.94 | 8.78 | 1.15 | 1,370.76 | 0.0408 | 15.15 | 21.94 | 8.27 | 227.04 | 17.70 | 18.97 | 13.22 |
| EIS Eczcb Ilc Sn ve Fn Ytm Sny ve Tct AS | 73.60m | 47.87m | 1.01bn | 352.00 | 21.13 | 2.55 | 20.52 | 13.75 | 1.36 | 1.36 | 2.10 | 11.30 | 0.1936 | 6.62 | 7.06 | 4,273,170.00 | 12.59 | 6.43 | 13.57 | 6.93 | 34.79 | 34.37 | 65.05 | 38.82 | 2.83 | -- | 0.0277 | 45.92 | 21.38 | 15.79 | 134.43 | 28.21 | -10.22 | -10.20 |
| Eckert & Zieglr Strahln und Mdzntchnk AG | 213.44m | 28.61m | 1.04bn | 945.00 | 35.71 | 5.11 | 26.87 | 4.86 | 1.37 | 1.37 | 10.23 | 9.59 | 0.5951 | 2.44 | 6.11 | 246,463.00 | 8.11 | 8.38 | 9.60 | 10.13 | 49.67 | 47.84 | 13.62 | 12.77 | 2.34 | 53.28 | 0.1848 | 35.57 | 2.44 | 5.52 | 62.20 | 27.08 | 40.17 | 24.82 |
| Cosmo Pharmaceuticals NV | 78.15m | 35.28m | 1.10bn | 292.00 | 33.32 | 2.23 | 22.84 | 14.12 | 1.86 | 1.86 | 4.29 | 27.83 | 0.1177 | 2.92 | 3.81 | 265,696.90 | 5.32 | -2.09 | 5.51 | -2.16 | 53.43 | 59.64 | 45.17 | -19.05 | 10.81 | -- | 0.268 | -- | 6.77 | -0.7776 | 374.29 | 2.30 | -14.33 | -- |
| FAES Farma SA | 436.76m | 85.99m | 1.13bn | 1.66k | 13.12 | -- | 10.75 | 2.58 | 0.2766 | 0.2766 | 1.38 | -- | -- | -- | -- | 262,951.20 | -- | 12.75 | -- | 15.07 | 63.33 | 63.51 | 19.72 | 18.09 | -- | -- | -- | -- | 4.82 | 11.76 | 14.62 | 17.84 | 37.75 | 18.23 |
| AddLife AB | 815.77m | 54.75m | 1.20bn | 2.20k | 22.71 | 2.81 | 10.25 | 1.47 | 4.87 | 4.87 | 72.64 | 39.40 | 0.7693 | 3.96 | 6.52 | 4,932,631.00 | 5.18 | 9.03 | 8.48 | 17.10 | 37.61 | 35.74 | 6.73 | 7.57 | 0.4418 | 6.13 | 0.5417 | 34.17 | 51.57 | -- | 38.78 | -- | -- | -- |
| Formycon AG | 38.98m | 76.73m | 1.25bn | 178.00 | 13.36 | 3.14 | 15.98 | 32.08 | 6.21 | 6.21 | 3.35 | 26.46 | 0.0871 | 61.10 | 2.47 | 227,935.70 | 17.17 | -6.59 | 17.81 | -7.39 | 31.97 | 29.53 | 197.04 | -8.86 | 2.12 | -- | 0.0456 | -- | 20.35 | 16.22 | -127.42 | -- | -2.05 | -- |
| Pharma Mar SA | 227.29m | 86.13m | 1.27bn | 477.00 | 14.52 | 5.90 | 13.91 | 5.59 | 4.77 | 4.52 | 12.58 | 11.75 | 0.6255 | 0.7861 | 8.24 | 476,496.80 | 23.70 | 16.04 | 31.01 | 24.70 | 94.46 | 91.18 | 37.89 | 20.58 | 2.72 | -- | 0.1612 | -- | -14.87 | 4.90 | -32.35 | -- | 5.07 | -- |
| Zealand Pharma A/S | 13.52m | -131.21m | 1.37bn | 203.00 | -- | 24.86 | -- | 100.97 | -22.13 | -25.89 | 2.27 | 7.91 | 0.0731 | 0.1002 | 1.76 | 283,371.80 | -70.93 | -27.88 | -88.11 | -32.49 | 94.20 | -- | -970.30 | -275.48 | 3.69 | -- | 0.575 | -- | -69.28 | -14.01 | 10.84 | -- | 53.47 | -- |
| Camurus AB | 79.95m | 2.61m | 1.37bn | 170.00 | 560.75 | 15.44 | 365.50 | 17.17 | 0.4815 | 0.4815 | 15.55 | 17.49 | 0.7643 | 0.9319 | 6.59 | 5,885,939.00 | 2.50 | -27.66 | 3.09 | -33.82 | 88.13 | 86.73 | 3.27 | -84.90 | 3.03 | 47.33 | 0.0253 | -- | 78.74 | 39.49 | 45.93 | -- | 1.59 | -- |
| Biotest AG | 505.00m | -70.89m | 1.53bn | 2.07k | -- | 2.48 | -- | 3.03 | -3.58 | -3.58 | 25.52 | 17.38 | 0.456 | 1.50 | 3.58 | 256,736.10 | -6.25 | -2.44 | -6.92 | -2.83 | 15.74 | 27.69 | -13.70 | -5.86 | 2.09 | -5.09 | 0.6138 | -- | 6.48 | 4.79 | -101.96 | -- | -32.84 | -- |
| Euroapi SAS | 943.90m | 2.00m | 1.61bn | 3.34k | 1,075.71 | 1.44 | 20.00 | 1.71 | 0.0159 | 0.0159 | 10.30 | 11.83 | -- | -- | -- | 282,435.70 | -- | -- | -- | -- | 16.44 | -- | 0.2225 | -- | 1.05 | 11.33 | 0.0363 | -- | -5.48 | -- | -150.79 | -- | -- | -- |
| Almirall SA | 843.74m | 18.72m | 1.71bn | 1.79k | 91.40 | 1.25 | 40.23 | 2.02 | 0.1028 | 0.1028 | 4.60 | 7.52 | 0.372 | 1.46 | 6.30 | 472,417.10 | 0.8255 | -0.7384 | 0.9264 | -0.8645 | 78.18 | 77.53 | 2.22 | -2.24 | 1.71 | 5.61 | 0.2104 | -- | 2.45 | 1.59 | -155.01 | -- | -2.82 | -- |
Data as of Dec 07 2022. Currency figures normalised to Pharma Mar SA's reporting currency: Euro EUR
7.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Nov 2022 | 375.39k | 2.02% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 237.56k | 1.28% |
| BlackRock Fund Advisorsas of 03 Nov 2022 | 188.27k | 1.02% |
| Goldman Sachs Asset Management LPas of 28 Feb 2021 | 115.49k | 0.62% |
| Santander Asset Management SA SGIICas of 30 Sep 2022 | 109.54k | 0.59% |
| Dimensional Fund Advisors LPas of 04 Nov 2022 | 81.02k | 0.44% |
| Credit Suisse AGas of 30 Sep 2022 | 68.42k | 0.37% |
| BlackRock Advisors (UK) Ltd.as of 03 Nov 2022 | 66.99k | 0.36% |
| Jupiter Asset Management Ltd.as of 31 Aug 2022 | 63.91k | 0.34% |
| MainFirst Affiliated Fund Managers (Deutschland) GmbHas of 30 Jul 2021 | 58.44k | 0.32% |
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
